The Future of Cannabinoid Science
GALYNA™ is the synthesis of institutional life sciences and legalized craft cannabis. Our team’s history of success includes 45+ years of organic skincare formulation among the biggest names in the industry, a cannabis brand’s original co-founding pioneer, and scientific testing and precision by an expert in the development of topical products.
How do we know it works?
We have spent years researching and developing advanced topical formulations, and running a vast range of specialist studies via an independent laboratory to demonstrate efficacy, skin rejuvenation and restoration to ensure the integrity of our research and findings.
We test for proven effectiveness using human skin samples ethically sourced from post-plastic surgeries. It is here, under the microscope and other biochemical studies, that we explore skin cell changes to develop effective solutions and guide GALYNA™ formulations into the future.
Study. 1 - Skin Metabolism
Your skin is the largest organ of the body and a healthy metabolism is crucial to your human health. Skin metabolism is important in controlling regrowth and detoxification properties. Increased metabolic activity is widely defined as: managing rates of cell turnover and regeneration, collagen production, and repairing damage from UV exposure and aging.
What We Learned
Our proprietary formulations encourage positive biotransformation, and cellular regeneration within 24 hours. Through laboratory testing, we discovered that our formulations can enhance skin metabolism up to 50% more than untreated skin, in a non-irritating manner, and increase healing.
Skin Metabolism Visual
Skin Metabolism
Skin Metabolism Visual
Study. 2 - Wound Healing
Keratinocytes (K17) are fluorescent green, and the nuclei of the cells colored blue.
Keratinocytes (K17) are fluorescent green, and the nuclei of the cells colored blue.
The study was led by our Chief Scientific Officer, who has previous experience specializing in prevention of the spread of infectious diseases through open wounds and has conducted topical wound healing development studies for the Department of Defense, National Institute of Health and other multinational organizations.
For this study, we sourced human skin explants and created wound beds to treat with our cannabinoid-infused, lanolin-based Repair formulation. These samples were tracked and observed for a week at 63x magnification. Stimulation of wound healing and re-epithelialization (ie. the resurfacing of a wound with new epithelium) of the wound bed was noted by production of keratinocytes (K-17).
​
What We Learned
A one-time application of Repair stimulated the production of keratin 17 (K17) a cytokeratin important for epithelial migration and wound healing. The data shows that through skin penetration, our cannabinoid-infused formulations are able to reach the intended target receptors and promote wound healing via K17 expression.
Study. 3 - Antibacterial
This study was conducted to determine the antibacterial/anti-acne effectiveness of GALYNA™ formulations against the bacteria, Cutibacterium acnes, which causes acne. Ex vivo human skin obtained via post-surgical elective surgery and under IRB protocol was prepared as 5mm explants. Cutibacterium acnes was inoculated to the surface for 2 hours incubation prior to treatment with Dream (cannabinoid-containing) and Dream base (no cannabinoids).
​
What We Learned
​
After 24h exposure and incubation, C. acnes bacterial densities were determined and a reduction in bacterial counts was logged. Cannabinoid-containing Dream formulation significantly reduced C. acnes compared to growth controls of C. acnes. Dream base composition (lacking cannabinoids) did not significantly reduce C. acnes.
Decrease in C. acnes bacteria post-treatment.
Decrease in C. acnes bacteria post-treatment.
Dream
Viability % Compared to PBS Control
Repair
Viability % Compared to PBS Control
Study. 4 - Non-Irritation
For this study, our proprietary Dream and Repair formulations were all tested extensively using an adapted common standard irritation protocol (OECD 439), against commonly known irritants. A formulation can pass as non-irritating when 50% of cells are still viable after 24hrs of application. Viability of human skin after treatment with CBD containing formulations was assessed over three 24h continuous treatments of 10uL where formulations were washed off and re-applied at each time point.
​
The formulations were compared to controls that were non-irritating, moderate irritants, and strong irritants. This shows that all formulations tested did not decrease the viability of tissue in a manner that would indicate irritation. Our formulations passed with human skin cells remaining at above that mark, beyond twice that duration and only dipping below 50% near 72hrs.
​
What We Learned
​
The exposure time required to decrease viability to 50% is called the ET50. A longer ET50 means that skin tissue can be exposed to treatments for longer times before viability is decreased to half of the original. All formulations tested had an ET50 over 24hrs and were much higher than the mild irritant standard. Therefore, the formulations were classified as non-irritating substances.
Study. 5 - Collagen Production
Our most recent study was conducted to assess the promotion of collagen production in Dream. As before, ex vivo human skin tissue was prepared and treated with Dream (A1) and the base (A2) formulation for analysis. Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), the most sensitive method for mRNA gene quantification, we were able to determine changes in collagen type I alpha 1 (COL1A1) gene expression in human skin following daily treatment with Dream. Type I collagen is the most abundant form of collagen in the human body.
​
What We Learned
After 72hrs, Dream (A1) showed a significant increase in COLIA1 gene expression, a Type I collagen, outperforming the base formula (A2) over 7- fold. Also in other studies not shown, the active formulation (A1) was non-irritating up to 72 hours as was demonstrated in the previous studies.
Curious to Learn More?
Sign up to receive our latest scientific data, research reports and to participate in future product development.